Navigation Links
Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published today in the New England Journal of Medicine ("A National Survey of Physician-Industry Relationships") on the extent of doctor and pharmaceutical company relationships, highlights the need for profession-wide and public policy reforms promoted by The Prescription Project. The article concludes that the existing, voluntary PhRMA (Pharmaceutical Research and Manufacturers of America) Code isn't working.

The Prescription Project offers solutions to this continuing crisis by outlining specific suggestions for academic medical centers, physician leadership and policy makers to end industry influence on medicine:

"The fact that 94% of physicians have relationships with pharmaceutical companies is a clear barrier to a trusting and effective doctor patient relationship. Academic medical centers and professional medical societies must take the lead in protecting public trust in the medical profession by adopting reforms," said David J. Rothman, PhD, Associate Director of The Prescription Project and president of Institute on Medicine as a Profession, which funded the NEJM study.

"Though the financial ties are extensive, the change we are advocating for can be made and must be made. One can look to the example of several leading academic medical centers to see that this approach can work. We now need a profession-wide adoption of those policies at all hospitals, physician practices and professional medical societies," Rothman continued.

"Legislators across the country are concerned about the influence of the pharmaceutical industry on doctors, and how it affects patient care and costs," said Rob Restuccia, Director of The Prescription Project. "Proposals to stem the tide of industry gifts and end data-mining are moving to the floors of state houses nationwide."

-- Today, New York legislators joined with national consumer and senior groups to introduce a pair of bills to end data-mining and restrict industry gifts.

-- Earlier this week, Minnesota state officials announced a joint effort with consumers and health groups there to strengthen the state's first-in-nation 1993 gift law.

-- Maine and Vermont legislators are debating gifts disclosure and data-mining bills now, and a hearing on an academic-detailing bill is scheduled in Maine next Monday.

"Our ability to support and strengthen coalitions in states like these is crucial to getting policies that preserve the doctor-patient trust in place," Restuccia said.

For more information, visit www.prescriptionproject.org .

Contact

for The Prescription Project
Diana Pisciotta, 617-784-5256
or
Terence Burke, 617-482-0042


'"/>




Related medicine technology :

1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
3. Top Line Results of Phase III Study in Acute Ischemic Stroke (DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
4. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
5. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. MUSC Research Offers Hope for Those Resistant to Depression Treatment
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Antibiotics Dont Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 6.35% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental ... 1,961 people during the April 22-23 event at the San Mateo Event Center. ... barriers to care, CDA Cares educates the public and policymakers about the importance of ...
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, ... diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into precision ... type of healthcare model in the diagnosis and treatment of brain tumors. Healthcare ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) ... Jim Walter Blvd, for an educational and exciting 2-day program. , An attendee ... hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and ...
Breaking Medicine News(10 mins):